Phase I Study of AG-221 in Subjects With Advanced Hematologic Malignancies With an IDH2 Mutation

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2014 by Agios Pharmaceuticals, Inc.
Sponsor:
Information provided by (Responsible Party):
Agios Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier:
NCT01915498
First received: July 31, 2013
Last updated: September 16, 2014
Last verified: September 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: January 2016
  Estimated Primary Completion Date: January 2016 (Final data collection date for primary outcome measure)